CYTOKINETICS, INCORPORATED Repayments of Long-Term Debt
CYTOKINETICS, INCORPORATED (CYTK) reported Repayments of Long-Term Debt of $6.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED repayments of long-term debt for the quarter ending 2026-06-30 was $3.59M, a 33.31% increase year-over-year.
- CYTOKINETICS, INCORPORATED repayments of long-term debt for the quarter ending 2026-03-31 was $2.73M, a 1.98% increase year-over-year.
- CYTOKINETICS, INCORPORATED repayments of long-term debt for the quarter ending 2025-12-31 was $2.72M, a 1.91% increase year-over-year.
- CYTOKINETICS, INCORPORATED repayments of long-term debt for the quarter ending 2025-09-30 was $2.71M, a 1.92% increase year-over-year.
- CYTOKINETICS, INCORPORATED repayments of long-term debt for fiscal 2025 was $10.81M, a 24.54% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED repayments of long-term debt for fiscal 2024 was $8.68M.
- CYTOKINETICS, INCORPORATED repayments of long-term debt for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- CYTOKINETICS, INCORPORATED repayments of long-term debt for fiscal 2022 was $47.65M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.33M 10-Q · filed 2026-08-06 | $9.05M derived: sum of 3 quarters · filed 2026-08-06 | $11.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.73M 10-Q · filed 2026-05-05 | $5.46M derived: sum of 2 quarters · filed 2026-05-05 | $8.17M derived: sum of 3 quarters · filed 2026-05-05 | $10.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.43M derived: sum of 2 quarters · filed 2026-02-26 | $8.13M derived: sum of 3 quarters · filed 2026-08-06 | $10.81M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.41M derived: sum of 2 quarters · filed 2026-08-06 | $8.09M 10-Q · filed 2025-11-05 | $10.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.38M 10-Q · filed 2026-08-06 | $8.05M derived: sum of 3 quarters · filed 2026-08-06 | $10.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.68M 10-Q · filed 2026-05-05 | $5.35M derived: sum of 2 quarters · filed 2026-05-05 | $8.01M derived: sum of 3 quarters · filed 2026-05-05 | $10.66M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.33M derived: sum of 2 quarters · filed 2026-02-26 | $7.97M derived: sum of 3 quarters · filed 2026-02-26 | $8.68M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.30M derived: sum of 2 quarters · filed 2025-11-05 | $6.01M 10-Q · filed 2025-11-05 | $6.01M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.35M 10-Q · filed 2025-08-07 | $3.35M derived: sum of 3 quarters · filed 2026-02-26 | $3.35M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $705.00K 10-Q · filed 2025-05-06 | $705.00K derived: sum of 2 quarters · filed 2026-02-26 | $705.00K derived: sum of 3 quarters · filed 2026-02-26 | $705.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $0.00 derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $0.00 derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $47.65M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 derived: sum of 2 quarters · filed 2023-11-03 | $47.65M 10-Q · filed 2023-11-03 | $47.65M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $47.65M 10-Q · filed 2023-08-03 | $47.65M derived: sum of 3 quarters · filed 2023-08-03 | $47.65M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $47.65M 10-Q · filed 2023-05-05 | $47.65M derived: sum of 2 quarters · filed 2023-05-05 | $47.65M derived: sum of 3 quarters · filed 2023-05-05 | $47.65M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $0.00 derived: sum of 3 quarters · filed 2023-03-01 | $0.00 10-K · filed 2023-03-01 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $0.00 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $0.00 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |